TruScreen predicts huge growth in China

TruScreen predicts huge growth in China
Within two years, it expects to have its cervical cancer detection devices in 200 hospitals in China. (Image: Getty)
Tamara Poi-Ngawhika
A medtech company commercialising an AI-enabled cervical cancer detection system reports it's making progress, despite an operating loss of $1.35 million.TruScreen predicts a growth surge in several global markets over the next two years.Pitt Street Research is bullish on the stock, with a research note valuing it at $0.065 per share as a base case – it's only trading at $0.024. The note is based on assumptions of a continued roll-out of TruScreen, using a market share-based approach. In an announcement to the NZX,...